Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
December 5, 2011 | CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 1,828 | $2.21 | 166,016 | |
September 14, 2012 | CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 1,900 | $5.04 | 196,014 | |
March 17, 2023 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 2,000 | -- | 16,430 | |
March 17, 2023 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 2,000 | -- | 18,429 | |
March 17, 2023 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 2,000 | -- | 4,667 | |
March 17, 2023 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 2,000 | -- | 30,099 | |
March 17, 2023 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 2,000 | -- | 9,666 | |
March 17, 2023 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 2,000 | -- | 9,666 | |
February 17, 2016 | Director, CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 2,000 | $1.27 | 117,521 | |
September 14, 2012 | SVP Corp Bus Strategy/IR | Form 4 | Open market or private purchase of non-derivative or derivative security | 2,000 | $4.93 | 18,787 | |
February 25, 2008 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 2,000 | $6.17 | 20,349 | |
March 15, 2006 | VP - Operations | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 2,000 | -- | 8,534 | |
February 19, 2010 | Interim CAO, Controller | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 2,040 | $2.94 | 2,040 | |
November 19, 2008 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 2,100 | $2.70 | 122,562 | |
March 15, 2006 | VP - Regulatory Affairs | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 2,369 | -- | 2,369 | |
January 14, 2011 | Chief Medical Officer | Form 4 | Open market or private purchase of non-derivative or derivative security | 2,499 | -- | 2,500 | |
June 13, 2022 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 2,500 | -- | 7,666 | |
June 13, 2022 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 2,500 | -- | 7,666 | |
September 20, 2018 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 2,500 | $2.70 | 18,091 | |
September 20, 2018 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 2,500 | $2.70 | 14,750 | |
April 9, 2018 | Director, Chairman, President and CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 2,500 | $2.30 | 20,200 | |
March 14, 2014 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 2,500 | $3.86 | 21,331 | |
October 15, 2012 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 2,500 | $2.36 | 122,042 | |
October 15, 2012 | Director | Form 4 | Exercise of in-the-money or at-the-money derivative security | 2,500 | $2.36 | 34,583 | |
August 29, 2012 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 2,500 | $4.65 | 68,427 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.